Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,39
KB1182-1,09
PKN108,62108,640,63
Msft-0,13
Nokia5,936,020,64
IBM1,10
Mercedes-Benz Group AG57,6757,690,05
PFE0,40
16.02.2026 18:00:58
Indexy online
AD Index online
select
AD Index online
 

  • 14.02.2026 2:00:00
Hyperion DEFI Inc (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
4,14 7,25 0,28 2 348 140
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.02.2026
Popis společnosti
Obecné informace
Název společnostiHyperion DeFi Inc
TickerHYPD
Kmenové akcie:Ordinary Shares
RICHYPD.O
ISIN-
Prioritní akciePreference Shares non voting
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 15.03.2025 13
Akcie v oběhu k 05.01.2026 8 472 659
MěnaUSD
Kontaktní informace
Ulice295 MADISON AVENUE, SUITE 2400
MěstoNEW YORK
PSČ10017
ZeměUnited States
Kontatní osobaEric Ribner
Funkce kontaktní osobyInvestor Relations
Telefon18 137 669 539
Fax13026365454
Kontatní telefon16 467 514 363

Business Summary: Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Hyperion DeFi Inc revenues increased from $29K to $317K. Net loss applicable to common stockholders decreased 78% to $6.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 93% to $355K (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 16.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary, DirectorHyunsu Jung2901.01.202617.06.2025
Chief Financial Officer, Treasurer, SecretaryDavid Knox3629.09.202529.09.2025
General CounselRobert Rubenstein-12.01.202612.01.2026